Lipodystrophy in patients with acromegaly receiving pegvisomant

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 9, 2008, Pages 3515-3518

  Bonert, Vivien S ^a,e   Kennedy, Laurence ^b   Petersenn, Stephan ^c   Barkan, Ariel ^d   Carmichael, John ^a   Melmed, Shlomo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; STEROID;

ABDOMINAL WALL; ACROMEGALY; ADULT; ARM; ARTICLE; BUTTOCK; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION SITE; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; LIPODYSTROPHY; MALE; PRIORITY JOURNAL; REMISSION; THIGH; TRANSSPHENOIDAL SURGERY;

EID: 51649099797     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0833     Document Type: Article

References (20)

1. Melmed S 2006 Medical progress: acromegaly. N Engl J Med 355:2558-2573
2. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
3. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
4. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ 2003 Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 149:521-527
5. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML 2005 Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684-5691
6. Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ 2006 Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur J Endocrinol 154:805-806
7. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H, Strasburger CJ 2006 Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 154:213-220
8. Garg A 2000 Lipodystrophies. Am J Med 108:143-152
9. Reeves WG, Allen BR, Tattersall RB 1980 Insulin-induced lipoatrophy: evidence for an immune pathogenesis. BMJ 280:1500-1503
10. Kayikcioglu A, Akyurek M, Erk Y 1996 Semicircular lipoatrophy after intragluteal injection of benzathine penicillin. J Pediatr 129:166-167
11. Dahl PR, Zalla MJ, Winkelmann RK 1996 Localized involutional lipoatrophy: a clinicopathologic study of 16 patients. J Am Acad Dermatol 35:523-528
12. Atmaca A, Erbas T 2005 Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly. Exp Clin Endocrinol Diabetes 113:340-343
13. Rosenbaum M, Gertner JM, Leibel RL 1989 Effects of systemic GH administration on regional adipose tissue distribution and metabolism in GH-deficient children. J Clin Endocrinol and Metab 69:1274-1281
14. Maffei P, Martini C, Pagano C, Sicolo N, Corbetti F 2006 Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Ann Intern Med 145:310-312
15. Marazuela M, Dauden E, Ocon E, Moure D, Nattero L 2007 Pegvisomant-induced lipohypertrophy: report of a case with histopathology. Ann Intern Med 147:741-743
16. Salomon F, Cuneo RC, Hesp R, Sonksen PH 1989 The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321:1797-1803
17. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J 2007 A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 92:1442-1445
18. Nam SY, Lobie PE 2000 The mechanism of effect of growth hormone on preadipocyte and adipocyte function. Obes Rev 1:73-86
19. Brook CG 1973 Effect of human growth hormone treatment on adipose tissue in children. Arch Dis Childhood 48:725-728
20. Holdaway IM, Rajasoorya C 1999 Epidemiology of acromegaly. Pituitary 2:29-41